Global Non-oncology Biopharmaceuticals Market 2022 by Company, Regions, Type and Application, Forecast to 2028
The Non-oncology Biopharmaceuticals market report provides a detailed analysis of global market size, regional and country-level market size, segmentation market growth, market share, competitive Landscape, sales analysis, impact of domestic and global market players, value chain optimization, trade regulations, recent developments, opportunities analysis, strategic market growth analysis, product launches, area marketplace expanding, and technological innovations.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-oncology Biopharmaceuticals market size is estimated to be worth US$ 304180 million in 2021 and is forecast to a readjusted size of USD 519380 million by 2028 with a CAGR of 7.9% during review period. Immunology accounting for % of the Non-oncology Biopharmaceuticals global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Biologics segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, and Novo Nordisk, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-oncology Biopharmaceuticals market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
Chapter 1, to describe Non-oncology Biopharmaceuticals product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-oncology Biopharmaceuticals, with revenue, gross margin and global market share of Non-oncology Biopharmaceuticals from 2019 to 2022.
Chapter 3, the Non-oncology Biopharmaceuticals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-oncology Biopharmaceuticals market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-oncology Biopharmaceuticals research findings and conclusion, appendix and data source.
According to our (Global Info Research) latest study, due to COVID-19 pandemic, the global Non-oncology Biopharmaceuticals market size is estimated to be worth US$ 304180 million in 2021 and is forecast to a readjusted size of USD 519380 million by 2028 with a CAGR of 7.9% during review period. Immunology accounting for % of the Non-oncology Biopharmaceuticals global market in 2021, is projected to value USD million by 2028, growing at a % CAGR in next six years. While Biologics segment is altered to a % CAGR between 2022 and 2028.
Global key companies of Non-oncology Biopharmaceuticals include Roche, Sanofi, Johnson & Johnson, Pfizer, and Novo Nordisk, etc. In terms of revenue, the global top four players hold a share over % in 2021.
Market segmentation
Non-oncology Biopharmaceuticals market is split by Type and by Application. For the period 2017-2028, the growth among segments provide accurate calculations and forecasts for revenue by Type and by Application. This analysis can help you expand your business by targeting qualified niche markets.
Market segment by Type, covers
- Biologics
- Biosimilars
- Immunology
- Endocrinology
- Others
- Roche
- Sanofi
- Johnson & Johnson
- Pfizer
- Novo Nordisk
- Novartis
- Merck
- Teva
- Eli Lilly
- Bristol-Myers Squibb
- GlaxoSmithKline
- UCB Pharma
- Amgen
- AbbVie
- Takeda
- AstraZeneca
- Mylan
- LEO Pharma
- Boehringer Ingelheim
- Alexion Pharmaceuticals
- Elusys Therapeutics
- Swedish Orphan Biovitrum
- Biogen
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia, and Rest of Asia-Pacific)
- South America (Brazil, Argentina, Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Non-oncology Biopharmaceuticals product scope, market overview, market opportunities, market driving force and market risks.
Chapter 2, to profile the top players of Non-oncology Biopharmaceuticals, with revenue, gross margin and global market share of Non-oncology Biopharmaceuticals from 2019 to 2022.
Chapter 3, the Non-oncology Biopharmaceuticals competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with revenue and growth rate by Type, application, from 2017 to 2028.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2017 to 2022.and Non-oncology Biopharmaceuticals market forecast, by regions, type and application, with revenue, from 2023 to 2028.
Chapter 11 and 12, to describe Non-oncology Biopharmaceuticals research findings and conclusion, appendix and data source.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Non-oncology Biopharmaceuticals
1.2 Classification of Non-oncology Biopharmaceuticals by Type
1.2.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2021
1.2.3 Biologics
1.2.4 Biosimilars
1.3 Global Non-oncology Biopharmaceuticals Market by Application
1.3.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Global Non-oncology Biopharmaceuticals Market Size & Forecast
1.5 Global Non-oncology Biopharmaceuticals Market Size and Forecast by Region
1.5.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-oncology Biopharmaceuticals Market Size by Region, (2017-2022)
1.5.3 North America Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.4 Europe Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.6 South America Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-oncology Biopharmaceuticals Market Drivers
1.6.2 Non-oncology Biopharmaceuticals Market Restraints
1.6.3 Non-oncology Biopharmaceuticals Trends Analysis
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Non-oncology Biopharmaceuticals Product and Solutions
2.1.4 Roche Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Non-oncology Biopharmaceuticals Product and Solutions
2.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
2.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Non-oncology Biopharmaceuticals Product and Solutions
2.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Novo Nordisk
2.5.1 Novo Nordisk Details
2.5.2 Novo Nordisk Major Business
2.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
2.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Novo Nordisk Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Non-oncology Biopharmaceuticals Product and Solutions
2.6.4 Novartis Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Non-oncology Biopharmaceuticals Product and Solutions
2.7.4 Merck Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck Recent Developments and Future Plans
2.8 Teva
2.8.1 Teva Details
2.8.2 Teva Major Business
2.8.3 Teva Non-oncology Biopharmaceuticals Product and Solutions
2.8.4 Teva Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Teva Recent Developments and Future Plans
2.9 Eli Lilly
2.9.1 Eli Lilly Details
2.9.2 Eli Lilly Major Business
2.9.3 Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
2.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Eli Lilly Recent Developments and Future Plans
2.10 Bristol-Myers Squibb
2.10.1 Bristol-Myers Squibb Details
2.10.2 Bristol-Myers Squibb Major Business
2.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
2.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
2.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 UCB Pharma
2.12.1 UCB Pharma Details
2.12.2 UCB Pharma Major Business
2.12.3 UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 UCB Pharma Recent Developments and Future Plans
2.13 Amgen
2.13.1 Amgen Details
2.13.2 Amgen Major Business
2.13.3 Amgen Non-oncology Biopharmaceuticals Product and Solutions
2.13.4 Amgen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Amgen Recent Developments and Future Plans
2.14 AbbVie
2.14.1 AbbVie Details
2.14.2 AbbVie Major Business
2.14.3 AbbVie Non-oncology Biopharmaceuticals Product and Solutions
2.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 AbbVie Recent Developments and Future Plans
2.15 Takeda
2.15.1 Takeda Details
2.15.2 Takeda Major Business
2.15.3 Takeda Non-oncology Biopharmaceuticals Product and Solutions
2.15.4 Takeda Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Takeda Recent Developments and Future Plans
2.16 AstraZeneca
2.16.1 AstraZeneca Details
2.16.2 AstraZeneca Major Business
2.16.3 AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
2.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 AstraZeneca Recent Developments and Future Plans
2.17 Mylan
2.17.1 Mylan Details
2.17.2 Mylan Major Business
2.17.3 Mylan Non-oncology Biopharmaceuticals Product and Solutions
2.17.4 Mylan Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Mylan Recent Developments and Future Plans
2.18 LEO Pharma
2.18.1 LEO Pharma Details
2.18.2 LEO Pharma Major Business
2.18.3 LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 LEO Pharma Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
2.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
2.20 Alexion Pharmaceuticals
2.20.1 Alexion Pharmaceuticals Details
2.20.2 Alexion Pharmaceuticals Major Business
2.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
2.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.21 Elusys Therapeutics
2.21.1 Elusys Therapeutics Details
2.21.2 Elusys Therapeutics Major Business
2.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
2.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Elusys Therapeutics Recent Developments and Future Plans
2.22 Swedish Orphan Biovitrum
2.22.1 Swedish Orphan Biovitrum Details
2.22.2 Swedish Orphan Biovitrum Major Business
2.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
2.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Swedish Orphan Biovitrum Recent Developments and Future Plans
2.23 Biogen
2.23.1 Biogen Details
2.23.2 Biogen Major Business
2.23.3 Biogen Non-oncology Biopharmaceuticals Product and Solutions
2.23.4 Biogen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Biogen Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Non-oncology Biopharmaceuticals Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-oncology Biopharmaceuticals Players Market Share in 2021
3.2.2 Top 10 Non-oncology Biopharmaceuticals Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
3.4 Non-oncology Biopharmaceuticals Mergers & Acquisitions
3.5 Non-oncology Biopharmaceuticals New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Non-oncology Biopharmaceuticals Revenue and Market Share by Type (2017-2022)
4.2 Global Non-oncology Biopharmaceuticals Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2017-2022)
5.2 Global Non-oncology Biopharmaceuticals Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
6.2 North America Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country
6.3.1 North America Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
6.3.2 United States Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
6.3.3 Canada Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
7.2 Europe Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.3.1 Europe Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
7.3.2 Germany Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.3 France Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.5 Russia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.6 Italy Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2017-2028)
8.3.2 China Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.3 Japan Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.5 India Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.7 Australia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
9.2 South America Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
9.3 South America Non-oncology Biopharmaceuticals Market Size by Country
9.3.1 South America Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
9.3.2 Brazil Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
10.3.2 Turkey Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10.3.4 UAE Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
1.1 Product Overview and Scope of Non-oncology Biopharmaceuticals
1.2 Classification of Non-oncology Biopharmaceuticals by Type
1.2.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Type: 2017 Versus 2021 Versus 2028
1.2.2 Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2021
1.2.3 Biologics
1.2.4 Biosimilars
1.3 Global Non-oncology Biopharmaceuticals Market by Application
1.3.1 Overview: Global Non-oncology Biopharmaceuticals Market Size by Application: 2017 Versus 2021 Versus 2028
1.3.2 Immunology
1.3.3 Endocrinology
1.3.4 Others
1.4 Global Non-oncology Biopharmaceuticals Market Size & Forecast
1.5 Global Non-oncology Biopharmaceuticals Market Size and Forecast by Region
1.5.1 Global Non-oncology Biopharmaceuticals Market Size by Region: 2017 VS 2021 VS 2028
1.5.2 Global Non-oncology Biopharmaceuticals Market Size by Region, (2017-2022)
1.5.3 North America Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.4 Europe Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.5 Asia-Pacific Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.6 South America Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.5.7 Middle East and Africa Non-oncology Biopharmaceuticals Market Size and Prospect (2017-2028)
1.6 Market Drivers, Restraints and Trends
1.6.1 Non-oncology Biopharmaceuticals Market Drivers
1.6.2 Non-oncology Biopharmaceuticals Market Restraints
1.6.3 Non-oncology Biopharmaceuticals Trends Analysis
2 COMPANY PROFILES
2.1 Roche
2.1.1 Roche Details
2.1.2 Roche Major Business
2.1.3 Roche Non-oncology Biopharmaceuticals Product and Solutions
2.1.4 Roche Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.1.5 Roche Recent Developments and Future Plans
2.2 Sanofi
2.2.1 Sanofi Details
2.2.2 Sanofi Major Business
2.2.3 Sanofi Non-oncology Biopharmaceuticals Product and Solutions
2.2.4 Sanofi Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.2.5 Sanofi Recent Developments and Future Plans
2.3 Johnson & Johnson
2.3.1 Johnson & Johnson Details
2.3.2 Johnson & Johnson Major Business
2.3.3 Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
2.3.4 Johnson & Johnson Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.3.5 Johnson & Johnson Recent Developments and Future Plans
2.4 Pfizer
2.4.1 Pfizer Details
2.4.2 Pfizer Major Business
2.4.3 Pfizer Non-oncology Biopharmaceuticals Product and Solutions
2.4.4 Pfizer Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.4.5 Pfizer Recent Developments and Future Plans
2.5 Novo Nordisk
2.5.1 Novo Nordisk Details
2.5.2 Novo Nordisk Major Business
2.5.3 Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
2.5.4 Novo Nordisk Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.5.5 Novo Nordisk Recent Developments and Future Plans
2.6 Novartis
2.6.1 Novartis Details
2.6.2 Novartis Major Business
2.6.3 Novartis Non-oncology Biopharmaceuticals Product and Solutions
2.6.4 Novartis Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.6.5 Novartis Recent Developments and Future Plans
2.7 Merck
2.7.1 Merck Details
2.7.2 Merck Major Business
2.7.3 Merck Non-oncology Biopharmaceuticals Product and Solutions
2.7.4 Merck Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.7.5 Merck Recent Developments and Future Plans
2.8 Teva
2.8.1 Teva Details
2.8.2 Teva Major Business
2.8.3 Teva Non-oncology Biopharmaceuticals Product and Solutions
2.8.4 Teva Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.8.5 Teva Recent Developments and Future Plans
2.9 Eli Lilly
2.9.1 Eli Lilly Details
2.9.2 Eli Lilly Major Business
2.9.3 Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
2.9.4 Eli Lilly Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.9.5 Eli Lilly Recent Developments and Future Plans
2.10 Bristol-Myers Squibb
2.10.1 Bristol-Myers Squibb Details
2.10.2 Bristol-Myers Squibb Major Business
2.10.3 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
2.10.4 Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.10.5 Bristol-Myers Squibb Recent Developments and Future Plans
2.11 GlaxoSmithKline
2.11.1 GlaxoSmithKline Details
2.11.2 GlaxoSmithKline Major Business
2.11.3 GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
2.11.4 GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.11.5 GlaxoSmithKline Recent Developments and Future Plans
2.12 UCB Pharma
2.12.1 UCB Pharma Details
2.12.2 UCB Pharma Major Business
2.12.3 UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.12.4 UCB Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.12.5 UCB Pharma Recent Developments and Future Plans
2.13 Amgen
2.13.1 Amgen Details
2.13.2 Amgen Major Business
2.13.3 Amgen Non-oncology Biopharmaceuticals Product and Solutions
2.13.4 Amgen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.13.5 Amgen Recent Developments and Future Plans
2.14 AbbVie
2.14.1 AbbVie Details
2.14.2 AbbVie Major Business
2.14.3 AbbVie Non-oncology Biopharmaceuticals Product and Solutions
2.14.4 AbbVie Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.14.5 AbbVie Recent Developments and Future Plans
2.15 Takeda
2.15.1 Takeda Details
2.15.2 Takeda Major Business
2.15.3 Takeda Non-oncology Biopharmaceuticals Product and Solutions
2.15.4 Takeda Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.15.5 Takeda Recent Developments and Future Plans
2.16 AstraZeneca
2.16.1 AstraZeneca Details
2.16.2 AstraZeneca Major Business
2.16.3 AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
2.16.4 AstraZeneca Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.16.5 AstraZeneca Recent Developments and Future Plans
2.17 Mylan
2.17.1 Mylan Details
2.17.2 Mylan Major Business
2.17.3 Mylan Non-oncology Biopharmaceuticals Product and Solutions
2.17.4 Mylan Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.17.5 Mylan Recent Developments and Future Plans
2.18 LEO Pharma
2.18.1 LEO Pharma Details
2.18.2 LEO Pharma Major Business
2.18.3 LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
2.18.4 LEO Pharma Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.18.5 LEO Pharma Recent Developments and Future Plans
2.19 Boehringer Ingelheim
2.19.1 Boehringer Ingelheim Details
2.19.2 Boehringer Ingelheim Major Business
2.19.3 Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
2.19.4 Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.19.5 Boehringer Ingelheim Recent Developments and Future Plans
2.20 Alexion Pharmaceuticals
2.20.1 Alexion Pharmaceuticals Details
2.20.2 Alexion Pharmaceuticals Major Business
2.20.3 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
2.20.4 Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.20.5 Alexion Pharmaceuticals Recent Developments and Future Plans
2.21 Elusys Therapeutics
2.21.1 Elusys Therapeutics Details
2.21.2 Elusys Therapeutics Major Business
2.21.3 Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
2.21.4 Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.21.5 Elusys Therapeutics Recent Developments and Future Plans
2.22 Swedish Orphan Biovitrum
2.22.1 Swedish Orphan Biovitrum Details
2.22.2 Swedish Orphan Biovitrum Major Business
2.22.3 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
2.22.4 Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.22.5 Swedish Orphan Biovitrum Recent Developments and Future Plans
2.23 Biogen
2.23.1 Biogen Details
2.23.2 Biogen Major Business
2.23.3 Biogen Non-oncology Biopharmaceuticals Product and Solutions
2.23.4 Biogen Non-oncology Biopharmaceuticals Revenue, Gross Margin and Market Share (2019, 2020, 2021, and 2022)
2.23.5 Biogen Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Non-oncology Biopharmaceuticals Revenue and Share by Players (2019, 2020, 2021, and 2022)
3.2 Market Concentration Rate
3.2.1 Top 3 Non-oncology Biopharmaceuticals Players Market Share in 2021
3.2.2 Top 10 Non-oncology Biopharmaceuticals Players Market Share in 2021
3.2.3 Market Competition Trend
3.3 Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
3.4 Non-oncology Biopharmaceuticals Mergers & Acquisitions
3.5 Non-oncology Biopharmaceuticals New Entrants and Expansion Plans
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Non-oncology Biopharmaceuticals Revenue and Market Share by Type (2017-2022)
4.2 Global Non-oncology Biopharmaceuticals Market Forecast by Type (2023-2028)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Non-oncology Biopharmaceuticals Revenue Market Share by Application (2017-2022)
5.2 Global Non-oncology Biopharmaceuticals Market Forecast by Application (2023-2028)
6 NORTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
6.1 North America Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
6.2 North America Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
6.3 North America Non-oncology Biopharmaceuticals Market Size by Country
6.3.1 North America Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
6.3.2 United States Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
6.3.3 Canada Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
6.3.4 Mexico Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7 EUROPE BY COUNTRY, BY TYPE, AND BY APPLICATION
7.1 Europe Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
7.2 Europe Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
7.3 Europe Non-oncology Biopharmaceuticals Market Size by Country
7.3.1 Europe Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
7.3.2 Germany Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.3 France Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.4 United Kingdom Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.5 Russia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
7.3.6 Italy Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8 ASIA-PACIFIC BY REGION, BY TYPE, AND BY APPLICATION
8.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
8.2 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
8.3 Asia-Pacific Non-oncology Biopharmaceuticals Market Size by Region
8.3.1 Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2017-2028)
8.3.2 China Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.3 Japan Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.4 South Korea Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.5 India Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.6 Southeast Asia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
8.3.7 Australia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
9 SOUTH AMERICA BY COUNTRY, BY TYPE, AND BY APPLICATION
9.1 South America Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
9.2 South America Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
9.3 South America Non-oncology Biopharmaceuticals Market Size by Country
9.3.1 South America Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
9.3.2 Brazil Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
9.3.3 Argentina Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10 MIDDLE EAST & AFRICA BY COUNTRY, BY TYPE, AND BY APPLICATION
10.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2017-2028)
10.2 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2017-2028)
10.3 Middle East & Africa Non-oncology Biopharmaceuticals Market Size by Country
10.3.1 Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2017-2028)
10.3.2 Turkey Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10.3.3 Saudi Arabia Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
10.3.4 UAE Non-oncology Biopharmaceuticals Market Size and Forecast (2017-2028)
11 RESEARCH FINDINGS AND CONCLUSION
12 APPENDIX
12.1 Methodology
12.2 Research Process and Data Source
12.3 Disclaimer
LIST OF TABLES
Table 1. Global Non-oncology Biopharmaceuticals Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-oncology Biopharmaceuticals Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-oncology Biopharmaceuticals Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Non-oncology Biopharmaceuticals Product and Solutions
Table 9. Roche Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Non-oncology Biopharmaceuticals Product and Solutions
Table 13. Sanofi Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 15. Johnson & Johnson Major Business
Table 16. Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
Table 17. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Non-oncology Biopharmaceuticals Product and Solutions
Table 21. Pfizer Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 23. Novo Nordisk Major Business
Table 24. Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
Table 25. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Non-oncology Biopharmaceuticals Product and Solutions
Table 29. Novartis Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Non-oncology Biopharmaceuticals Product and Solutions
Table 33. Merck Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Teva Corporate Information, Head Office, and Major Competitors
Table 35. Teva Major Business
Table 36. Teva Non-oncology Biopharmaceuticals Product and Solutions
Table 37. Teva Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 39. Eli Lilly Major Business
Table 40. Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
Table 41. Eli Lilly Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 43. Bristol-Myers Squibb Major Business
Table 44. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
Table 45. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
Table 49. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. UCB Pharma Corporate Information, Head Office, and Major Competitors
Table 51. UCB Pharma Major Business
Table 52. UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 53. UCB Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Amgen Corporate Information, Head Office, and Major Competitors
Table 55. Amgen Major Business
Table 56. Amgen Non-oncology Biopharmaceuticals Product and Solutions
Table 57. Amgen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. AbbVie Corporate Information, Head Office, and Major Competitors
Table 59. AbbVie Major Business
Table 60. AbbVie Non-oncology Biopharmaceuticals Product and Solutions
Table 61. AbbVie Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Takeda Corporate Information, Head Office, and Major Competitors
Table 63. Takeda Major Business
Table 64. Takeda Non-oncology Biopharmaceuticals Product and Solutions
Table 65. Takeda Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 67. AstraZeneca Major Business
Table 68. AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
Table 69. AstraZeneca Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Mylan Corporate Information, Head Office, and Major Competitors
Table 71. Mylan Major Business
Table 72. Mylan Non-oncology Biopharmaceuticals Product and Solutions
Table 73. Mylan Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. LEO Pharma Corporate Information, Head Office, and Major Competitors
Table 75. LEO Pharma Major Business
Table 76. LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 77. LEO Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 79. Boehringer Ingelheim Major Business
Table 80. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
Table 81. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 83. Alexion Pharmaceuticals Major Business
Table 84. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
Table 85. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Elusys Therapeutics Corporate Information, Head Office, and Major Competitors
Table 87. Elusys Therapeutics Major Business
Table 88. Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
Table 89. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Swedish Orphan Biovitrum Corporate Information, Head Office, and Major Competitors
Table 91. Swedish Orphan Biovitrum Major Business
Table 92. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
Table 93. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Biogen Corporate Information, Head Office, and Major Competitors
Table 95. Biogen Major Business
Table 96. Biogen Non-oncology Biopharmaceuticals Product and Solutions
Table 97. Biogen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 99. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 100. Breakdown of Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
Table 102. Non-oncology Biopharmaceuticals Mergers & Acquisitions in the Past Five Years
Table 103. Non-oncology Biopharmaceuticals New Entrants and Expansion Plans
Table 104. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Type (2017-2022)
Table 105. Global Non-oncology Biopharmaceuticals Revenue Share by Type (2017-2022)
Table 106. Global Non-oncology Biopharmaceuticals Revenue Forecast by Type (2023-2028)
Table 107. Global Non-oncology Biopharmaceuticals Revenue by Application (2017-2022)
Table 108. Global Non-oncology Biopharmaceuticals Revenue Forecast by Application (2023-2028)
Table 109. North America Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 110. North America Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 111. North America Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 112. North America Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 113. North America Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 114. North America Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 115. Europe Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 116. Europe Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 117. Europe Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 118. Europe Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 119. Europe Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 120. Europe Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 121. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 122. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 123. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 124. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 125. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2017-2022) & (USD Million)
Table 126. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2023-2028) & (USD Million)
Table 127. South America Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 128. South America Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 129. South America Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 130. South America Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 131. South America Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 132. South America Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 133. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 134. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 135. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 136. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 137. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 138. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 1. Global Non-oncology Biopharmaceuticals Revenue by Type, (USD Million), 2017 VS 2021 VS 2028
Table 2. Global Non-oncology Biopharmaceuticals Revenue by Application, (USD Million), 2017 VS 2021 VS 2028
Table 3. Global Market Non-oncology Biopharmaceuticals Revenue (Million USD) Comparison by Region (2017 VS 2021 VS 2028)
Table 4. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Region (2017-2022)
Table 5. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2023-2028)
Table 6. Roche Corporate Information, Head Office, and Major Competitors
Table 7. Roche Major Business
Table 8. Roche Non-oncology Biopharmaceuticals Product and Solutions
Table 9. Roche Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 10. Sanofi Corporate Information, Head Office, and Major Competitors
Table 11. Sanofi Major Business
Table 12. Sanofi Non-oncology Biopharmaceuticals Product and Solutions
Table 13. Sanofi Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 14. Johnson & Johnson Corporate Information, Head Office, and Major Competitors
Table 15. Johnson & Johnson Major Business
Table 16. Johnson & Johnson Non-oncology Biopharmaceuticals Product and Solutions
Table 17. Johnson & Johnson Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 18. Pfizer Corporate Information, Head Office, and Major Competitors
Table 19. Pfizer Major Business
Table 20. Pfizer Non-oncology Biopharmaceuticals Product and Solutions
Table 21. Pfizer Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 22. Novo Nordisk Corporate Information, Head Office, and Major Competitors
Table 23. Novo Nordisk Major Business
Table 24. Novo Nordisk Non-oncology Biopharmaceuticals Product and Solutions
Table 25. Novo Nordisk Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 26. Novartis Corporate Information, Head Office, and Major Competitors
Table 27. Novartis Major Business
Table 28. Novartis Non-oncology Biopharmaceuticals Product and Solutions
Table 29. Novartis Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 30. Merck Corporate Information, Head Office, and Major Competitors
Table 31. Merck Major Business
Table 32. Merck Non-oncology Biopharmaceuticals Product and Solutions
Table 33. Merck Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 34. Teva Corporate Information, Head Office, and Major Competitors
Table 35. Teva Major Business
Table 36. Teva Non-oncology Biopharmaceuticals Product and Solutions
Table 37. Teva Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 38. Eli Lilly Corporate Information, Head Office, and Major Competitors
Table 39. Eli Lilly Major Business
Table 40. Eli Lilly Non-oncology Biopharmaceuticals Product and Solutions
Table 41. Eli Lilly Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 42. Bristol-Myers Squibb Corporate Information, Head Office, and Major Competitors
Table 43. Bristol-Myers Squibb Major Business
Table 44. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Product and Solutions
Table 45. Bristol-Myers Squibb Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 46. GlaxoSmithKline Corporate Information, Head Office, and Major Competitors
Table 47. GlaxoSmithKline Major Business
Table 48. GlaxoSmithKline Non-oncology Biopharmaceuticals Product and Solutions
Table 49. GlaxoSmithKline Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 50. UCB Pharma Corporate Information, Head Office, and Major Competitors
Table 51. UCB Pharma Major Business
Table 52. UCB Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 53. UCB Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 54. Amgen Corporate Information, Head Office, and Major Competitors
Table 55. Amgen Major Business
Table 56. Amgen Non-oncology Biopharmaceuticals Product and Solutions
Table 57. Amgen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 58. AbbVie Corporate Information, Head Office, and Major Competitors
Table 59. AbbVie Major Business
Table 60. AbbVie Non-oncology Biopharmaceuticals Product and Solutions
Table 61. AbbVie Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 62. Takeda Corporate Information, Head Office, and Major Competitors
Table 63. Takeda Major Business
Table 64. Takeda Non-oncology Biopharmaceuticals Product and Solutions
Table 65. Takeda Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 66. AstraZeneca Corporate Information, Head Office, and Major Competitors
Table 67. AstraZeneca Major Business
Table 68. AstraZeneca Non-oncology Biopharmaceuticals Product and Solutions
Table 69. AstraZeneca Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 70. Mylan Corporate Information, Head Office, and Major Competitors
Table 71. Mylan Major Business
Table 72. Mylan Non-oncology Biopharmaceuticals Product and Solutions
Table 73. Mylan Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 74. LEO Pharma Corporate Information, Head Office, and Major Competitors
Table 75. LEO Pharma Major Business
Table 76. LEO Pharma Non-oncology Biopharmaceuticals Product and Solutions
Table 77. LEO Pharma Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 78. Boehringer Ingelheim Corporate Information, Head Office, and Major Competitors
Table 79. Boehringer Ingelheim Major Business
Table 80. Boehringer Ingelheim Non-oncology Biopharmaceuticals Product and Solutions
Table 81. Boehringer Ingelheim Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 82. Alexion Pharmaceuticals Corporate Information, Head Office, and Major Competitors
Table 83. Alexion Pharmaceuticals Major Business
Table 84. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Product and Solutions
Table 85. Alexion Pharmaceuticals Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 86. Elusys Therapeutics Corporate Information, Head Office, and Major Competitors
Table 87. Elusys Therapeutics Major Business
Table 88. Elusys Therapeutics Non-oncology Biopharmaceuticals Product and Solutions
Table 89. Elusys Therapeutics Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 90. Swedish Orphan Biovitrum Corporate Information, Head Office, and Major Competitors
Table 91. Swedish Orphan Biovitrum Major Business
Table 92. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Product and Solutions
Table 93. Swedish Orphan Biovitrum Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 94. Biogen Corporate Information, Head Office, and Major Competitors
Table 95. Biogen Major Business
Table 96. Biogen Non-oncology Biopharmaceuticals Product and Solutions
Table 97. Biogen Non-oncology Biopharmaceuticals Revenue (USD Million), Gross Margin and Market Share (2019, 2020, 2021, and 2022)
Table 98. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Players (2019, 2020, 2021, and 2022)
Table 99. Global Non-oncology Biopharmaceuticals Revenue Share by Players (2019, 2020, 2021, and 2022)
Table 100. Breakdown of Non-oncology Biopharmaceuticals by Company Type (Tier 1, Tier 2 and Tier 3)
Table 101. Non-oncology Biopharmaceuticals Players Head Office, Products and Services Provided
Table 102. Non-oncology Biopharmaceuticals Mergers & Acquisitions in the Past Five Years
Table 103. Non-oncology Biopharmaceuticals New Entrants and Expansion Plans
Table 104. Global Non-oncology Biopharmaceuticals Revenue (USD Million) by Type (2017-2022)
Table 105. Global Non-oncology Biopharmaceuticals Revenue Share by Type (2017-2022)
Table 106. Global Non-oncology Biopharmaceuticals Revenue Forecast by Type (2023-2028)
Table 107. Global Non-oncology Biopharmaceuticals Revenue by Application (2017-2022)
Table 108. Global Non-oncology Biopharmaceuticals Revenue Forecast by Application (2023-2028)
Table 109. North America Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 110. North America Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 111. North America Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 112. North America Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 113. North America Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 114. North America Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 115. Europe Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 116. Europe Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 117. Europe Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 118. Europe Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 119. Europe Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 120. Europe Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 121. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 122. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 123. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 124. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 125. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2017-2022) & (USD Million)
Table 126. Asia-Pacific Non-oncology Biopharmaceuticals Revenue by Region (2023-2028) & (USD Million)
Table 127. South America Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 128. South America Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 129. South America Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 130. South America Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 131. South America Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 132. South America Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
Table 133. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2017-2022) & (USD Million)
Table 134. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Type (2023-2028) & (USD Million)
Table 135. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2017-2022) & (USD Million)
Table 136. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Application (2023-2028) & (USD Million)
Table 137. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2017-2022) & (USD Million)
Table 138. Middle East & Africa Non-oncology Biopharmaceuticals Revenue by Country (2023-2028) & (USD Million)
LIST OF FIGURES
Figure 1. Non-oncology Biopharmaceuticals Picture
Figure 2. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2021
Figure 3. Biologics
Figure 4. Biosimilars
Figure 5. Non-oncology Biopharmaceuticals Revenue Market Share by Application in 2021
Figure 6. Immunology Picture
Figure 7. Endocrinology Picture
Figure 8. Others Picture
Figure 9. Global Non-oncology Biopharmaceuticals Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Non-oncology Biopharmaceuticals Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2017-2028)
Figure 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region in 2021
Figure 13. North America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Non-oncology Biopharmaceuticals Market Drivers
Figure 19. Non-oncology Biopharmaceuticals Market Restraints
Figure 20. Non-oncology Biopharmaceuticals Market Trends
Figure 21. Roche Recent Developments and Future Plans
Figure 22. Sanofi Recent Developments and Future Plans
Figure 23. Johnson & Johnson Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Novo Nordisk Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Merck Recent Developments and Future Plans
Figure 28. Teva Recent Developments and Future Plans
Figure 29. Eli Lilly Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. UCB Pharma Recent Developments and Future Plans
Figure 33. Amgen Recent Developments and Future Plans
Figure 34. AbbVie Recent Developments and Future Plans
Figure 35. Takeda Recent Developments and Future Plans
Figure 36. AstraZeneca Recent Developments and Future Plans
Figure 37. Mylan Recent Developments and Future Plans
Figure 38. LEO Pharma Recent Developments and Future Plans
Figure 39. Boehringer Ingelheim Recent Developments and Future Plans
Figure 40. Alexion Pharmaceuticals Recent Developments and Future Plans
Figure 41. Elusys Therapeutics Recent Developments and Future Plans
Figure 42. Swedish Orphan Biovitrum Recent Developments and Future Plans
Figure 43. Biogen Recent Developments and Future Plans
Figure 44. Global Non-oncology Biopharmaceuticals Revenue Share by Players in 2021
Figure 45. Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2021
Figure 47. Global Top 10 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global Non-oncology Biopharmaceuticals Revenue Share by Type in 2021
Figure 50. Global Non-oncology Biopharmaceuticals Market Share Forecast by Type (2023-2028)
Figure 51. Global Non-oncology Biopharmaceuticals Revenue Share by Application in 2021
Figure 52. Global Non-oncology Biopharmaceuticals Market Share Forecast by Application (2023-2028)
Figure 53. North America Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 54. North America Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 55. North America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 56. United States Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 60. Europe Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 61. Europe Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 62. Germany Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific Non-oncology Biopharmaceuticals Revenue Market Share by Region (2017-2028)
Figure 70. China Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 77. South America Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 78. South America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 79. Brazil Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 84. Turkey Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
Figure 1. Non-oncology Biopharmaceuticals Picture
Figure 2. Global Non-oncology Biopharmaceuticals Revenue Market Share by Type in 2021
Figure 3. Biologics
Figure 4. Biosimilars
Figure 5. Non-oncology Biopharmaceuticals Revenue Market Share by Application in 2021
Figure 6. Immunology Picture
Figure 7. Endocrinology Picture
Figure 8. Others Picture
Figure 9. Global Non-oncology Biopharmaceuticals Market Size, (USD Million): 2017 VS 2021 VS 2028
Figure 10. Global Non-oncology Biopharmaceuticals Revenue and Forecast (2017-2028) & (USD Million)
Figure 11. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region (2017-2028)
Figure 12. Global Non-oncology Biopharmaceuticals Revenue Market Share by Region in 2021
Figure 13. North America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 14. Europe Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 15. Asia-Pacific Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 16. South America Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 17. Middle East and Africa Non-oncology Biopharmaceuticals Revenue (USD Million) and Growth Rate (2017-2028)
Figure 18. Non-oncology Biopharmaceuticals Market Drivers
Figure 19. Non-oncology Biopharmaceuticals Market Restraints
Figure 20. Non-oncology Biopharmaceuticals Market Trends
Figure 21. Roche Recent Developments and Future Plans
Figure 22. Sanofi Recent Developments and Future Plans
Figure 23. Johnson & Johnson Recent Developments and Future Plans
Figure 24. Pfizer Recent Developments and Future Plans
Figure 25. Novo Nordisk Recent Developments and Future Plans
Figure 26. Novartis Recent Developments and Future Plans
Figure 27. Merck Recent Developments and Future Plans
Figure 28. Teva Recent Developments and Future Plans
Figure 29. Eli Lilly Recent Developments and Future Plans
Figure 30. Bristol-Myers Squibb Recent Developments and Future Plans
Figure 31. GlaxoSmithKline Recent Developments and Future Plans
Figure 32. UCB Pharma Recent Developments and Future Plans
Figure 33. Amgen Recent Developments and Future Plans
Figure 34. AbbVie Recent Developments and Future Plans
Figure 35. Takeda Recent Developments and Future Plans
Figure 36. AstraZeneca Recent Developments and Future Plans
Figure 37. Mylan Recent Developments and Future Plans
Figure 38. LEO Pharma Recent Developments and Future Plans
Figure 39. Boehringer Ingelheim Recent Developments and Future Plans
Figure 40. Alexion Pharmaceuticals Recent Developments and Future Plans
Figure 41. Elusys Therapeutics Recent Developments and Future Plans
Figure 42. Swedish Orphan Biovitrum Recent Developments and Future Plans
Figure 43. Biogen Recent Developments and Future Plans
Figure 44. Global Non-oncology Biopharmaceuticals Revenue Share by Players in 2021
Figure 45. Non-oncology Biopharmaceuticals Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2021
Figure 46. Global Top 3 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2021
Figure 47. Global Top 10 Players Non-oncology Biopharmaceuticals Revenue Market Share in 2021
Figure 48. Key Players Market Share Trend (Top 3 Market Share: 2020 VS 2021 VS 2022)
Figure 49. Global Non-oncology Biopharmaceuticals Revenue Share by Type in 2021
Figure 50. Global Non-oncology Biopharmaceuticals Market Share Forecast by Type (2023-2028)
Figure 51. Global Non-oncology Biopharmaceuticals Revenue Share by Application in 2021
Figure 52. Global Non-oncology Biopharmaceuticals Market Share Forecast by Application (2023-2028)
Figure 53. North America Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 54. North America Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 55. North America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 56. United States Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 57. Canada Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 58. Mexico Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 59. Europe Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 60. Europe Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 61. Europe Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 62. Germany Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 63. France Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 64. United Kingdom Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 65. Russia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 66. Italy Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 67. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 68. Asia-Pacific Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 69. Asia-Pacific Non-oncology Biopharmaceuticals Revenue Market Share by Region (2017-2028)
Figure 70. China Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 71. Japan Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 72. South Korea Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 73. India Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 74. Southeast Asia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 75. Australia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 76. South America Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 77. South America Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 78. South America Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 79. Brazil Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 80. Argentina Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 81. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Type (2017-2028)
Figure 82. Middle East and Africa Non-oncology Biopharmaceuticals Sales Market Share by Application (2017-2028)
Figure 83. Middle East and Africa Non-oncology Biopharmaceuticals Revenue Market Share by Country (2017-2028)
Figure 84. Turkey Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 85. Saudi Arabia Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 86. UAE Non-oncology Biopharmaceuticals Revenue and Growth Rate (2017-2028) & (USD Million)
Figure 87. Methodology
Figure 88. Research Process and Data Source
